As filed with the Securities and Exchange Commission on November 26, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 101 ...

As filed with the Securities and Exchange Commission on September 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 101 ...

Core Insights - Psyence BioMed is advancing its mission to develop safe and effective psychedelic therapies for mental health challenges, with significant progress in clinical development, regulatory compliance, and strategic partnerships [2][11][14] Clinical Development - The company is executing a clinical trial in partnership with Southern Star Research, aiming to expand patient access and accelerate enrollment [3] - A Steering Committee has been established to guide the development of a study on psilocybin for Alcohol Use Disorder, with plans to conduct the study in South Africa [6] - The partnership with PsyLabs is crucial for the Ibogaine program, with successful production of a GMP-aligned Ibogaine Total Alkaloid extract [7][9] Financial Position - As of August 4, 2025, Psyence BioMed reported a strong cash balance of $11.4 million and no outstanding debt, positioning the company for growth opportunities [11] - The company regained compliance with Nasdaq listing requirements in June 2025, marking a significant milestone in its growth [12] Strategic Vision - The company aims to build a resilient biotechnology firm focused on nature-derived psychedelic therapies, with a commitment to long-term value creation [14][18] - Psyence BioMed is positioned to lead in ethical and scalable production of ibogaine, leveraging its unique sourcing capabilities in Africa [17] Market Outlook - The global market for psilocybin-assisted therapy is projected to grow from $1.5 billion in 2024 to $3.3 billion by 2031, driven by increasing acceptance of psychedelic therapies [27][18]

Business Combination Highlights - Non-atai Beckley Psytech shareholders will receive approximately 105 million newly issued shares of atai common stock, representing about 31% of the pro forma entity[14] - Closing is expected in the second half of 2025, pending atai shareholder approval[14] - Approximately 25% of atai's common stock has entered into voting agreements supporting the transaction[14] BPL-003 Clinical Trial Results and Design - Phase 1 results showed perceptual effects generally resolving in under 90 minutes[40] - Phase 2a Part 1 (Monotherapy Cohort) data showed a mean MADRS reduction of approximately 13 points at Day 2, sustained to Day 85[53] - In Phase 2a Part 1, 55% of patients met response criteria one day after a single 10mg dose of BPL-003[53] - In Phase 2a Part 1, 55% of patients met clinical remission criteria one month after a single dose, with 45% meeting remission criteria at day 85[53] - In Phase 2a, approximately 90% of drug-related AEs occurred on the day of dosing, and all were resolved without intervention[60] - Phase 2b clinical trial is a randomized, quadruple-masked, monotherapy study in approximately 196 moderate to severe TRD patients[62] Market Opportunity - SPRAVATO achieved blockbuster status in 2024 with sales exceeding $1 billion, with approximately 86% of sales in the US[24] - Johnson & Johnson highlights SPRAVATO as a "key franchise" guiding $3 billion to $3.5 billion in annual sales[28]

As filed with the Securities and Exchange Commission on September 13, 2023. Registration No. 333-273293 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) | British Columbia | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organ ...

As filed with the Securities and Exchange Commission on July 25, 2023. Registration No. 333-273293 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) | British Columbia | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code Number) | Identification Number) | 101 – 1220 West 6 Avenue Vancouver, B ...

As filed with the Securities and Exchange Commission on July 17, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 101 – 12 ...

As filed with the Securities and Exchange Commission on March 28, 2023. Registration No. 333-270859 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) | British Columbia | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organizat ...

As filed with the Securities and Exchange Commission on March 27, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CONFIDENTIAL SUBMISSION ON FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box. ☒ If this form is filed to register additional securit ...